Therapeutic needs revive arsenic compound

Pharmaceutical Science and Technology Today

Volumn 3, Issue 12, 2000, Pages 401-

  Bradley, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; RETINOIC ACID; VASCULOTROPIN;

ACUTE MYELOBLASTIC LEUKEMIA; ANGIOGENESIS; APOPTOSIS; BONE MARROW NECROSIS; CLINICAL TRIAL; CYTOLYSIS; DIARRHEA; DRUG APPROVAL; DRUG MECHANISM; DYSPNEA; EDEMA; FATIGUE; FEVER; HEADACHE; HUMAN; HYPERGLYCEMIA; LEUKEMIA REMISSION; LEUKOCYTOSIS; MYALGIA; NAUSEA; SHORT SURVEY; VERTIGO; VOMITING; WEIGHT GAIN;

EID: 0034405156     PISSN: 14615347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1461-5347(00)00318-7     Document Type: Short Survey

References (3)

1. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide
2. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide
3. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis